Rectal Cancer

Mobetron extends survival rates and reduces tumor recurrence in rectal cancer

Published in Women's Health Weekly, March 30th, 2006

The U.S. Food & Drug Administration (FDA)-approved mobile electron-beam system known as the Mobetron, developed by Intraop Medical Corporation of Sunnyvale, California, has proven clinically successful in extending survival rates and reducing tumor recurrence rates in patients with advanced rectal cancer.

The Mobetron delivers radiation directly to the tumor bed as part of colorectal cancer surgery. This is the ideal time to radiologically cleanse the area of any errant cancer cells that might have escaped removal. This technique is known as intraoperative radiation therapy (IORT).

In the recent European clinical study, 651 women and men with locally...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2006-03-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry